img

Global Chemotherapy-induced Nausea and Vomiting Treatment Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Chemotherapy-induced Nausea and Vomiting Treatment Market Insights, Forecast to 2034

Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families.
Market Analysis and InsightsGlobal Chemotherapy-induced Nausea and Vomiting Treatment Market
The global Chemotherapy-induced Nausea and Vomiting Treatment market is projected to grow from US$ million in 2024 to US$ million by 2034, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Chemotherapy-induced Nausea and Vomiting Treatment is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Chemotherapy-induced Nausea and Vomiting Treatment is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Chemotherapy-induced Nausea and Vomiting Treatment is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The global key companies of Chemotherapy-induced Nausea and Vomiting Treatment include Heron Therapeutics, Merck, Eisai, Mundipharma, Qilu Pharma, Teva, Novartis, Roche and Mylan, etc. in 2022, the global top five players had a share approximately % in terms of revenue.
Report Includes
This report presents an overview of global market for Chemotherapy-induced Nausea and Vomiting Treatment market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2024, and projections of CAGR through 2034.
This report researches the key producers of Chemotherapy-induced Nausea and Vomiting Treatment, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Chemotherapy-induced Nausea and Vomiting Treatment, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Chemotherapy-induced Nausea and Vomiting Treatment revenue, market share and industry ranking of main companies, data from 2018 to 2024. Identification of the major stakeholders in the global Chemotherapy-induced Nausea and Vomiting Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2034. Evaluation and forecast the market size for Chemotherapy-induced Nausea and Vomiting Treatment revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Heron Therapeutics, Merck, Eisai, Mundipharma, Qilu Pharma, Teva, Novartis, Roche and Mylan, etc.



By Company


Heron Therapeutics
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Roche
Mylan
Baxter
GSK
Helsinn
Southwest Pharma
Haisco
Sun Pharma
Segment by Type
5-HT3 Inhibitors
NK1 Inhibitors
Other

Segment by Application


Acute CINV
Delayed CINV
Breakthrough CINV
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Revenue of Chemotherapy-induced Nausea and Vomiting Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3Detailed analysis of Chemotherapy-induced Nausea and Vomiting Treatment companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8China by type and by application revenue for each segment.
Chapter 9Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Chemotherapy-induced Nausea and Vomiting Treatment revenue, gross margin, and recent development, etc.
Chapter 12Analyst's Viewpoints/Conclusions

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chemotherapy-induced Nausea and Vomiting Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 5-HT3 Inhibitors
1.2.3 NK1 Inhibitors
1.2.4 Other
1.3 Market by Application
1.3.1 Global Chemotherapy-induced Nausea and Vomiting Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Acute CINV
1.3.3 Delayed CINV
1.3.4 Breakthrough CINV
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chemotherapy-induced Nausea and Vomiting Treatment Market Perspective (2018-2034)
2.2 Global Chemotherapy-induced Nausea and Vomiting Treatment Growth Trends by Region
2.2.1 Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Region: 2018 VS 2022 VS 2034
2.2.2 Chemotherapy-induced Nausea and Vomiting Treatment Historic Market Size by Region (2018-2024)
2.2.3 Chemotherapy-induced Nausea and Vomiting Treatment Forecasted Market Size by Region (2024-2034)
2.3 Chemotherapy-induced Nausea and Vomiting Treatment Market Dynamics
2.3.1 Chemotherapy-induced Nausea and Vomiting Treatment Industry Trends
2.3.2 Chemotherapy-induced Nausea and Vomiting Treatment Market Drivers
2.3.3 Chemotherapy-induced Nausea and Vomiting Treatment Market Challenges
2.3.4 Chemotherapy-induced Nausea and Vomiting Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Chemotherapy-induced Nausea and Vomiting Treatment by Players
3.1.1 Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Players (2018-2024)
3.1.2 Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue Market Share by Players (2018-2024)
3.2 Global Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Chemotherapy-induced Nausea and Vomiting Treatment, Ranking by Revenue, 2021 VS 2022 VS 2024
3.4 Global Chemotherapy-induced Nausea and Vomiting Treatment Market Concentration Ratio
3.4.1 Global Chemotherapy-induced Nausea and Vomiting Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chemotherapy-induced Nausea and Vomiting Treatment Revenue in 2022
3.5 Global Key Players of Chemotherapy-induced Nausea and Vomiting Treatment Head office and Area Served
3.6 Global Key Players of Chemotherapy-induced Nausea and Vomiting Treatment, Product and Application
3.7 Global Key Players of Chemotherapy-induced Nausea and Vomiting Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Chemotherapy-induced Nausea and Vomiting Treatment Breakdown Data by Type
4.1 Global Chemotherapy-induced Nausea and Vomiting Treatment Historic Market Size by Type (2018-2024)
4.2 Global Chemotherapy-induced Nausea and Vomiting Treatment Forecasted Market Size by Type (2024-2034)
5 Chemotherapy-induced Nausea and Vomiting Treatment Breakdown Data by Application
5.1 Global Chemotherapy-induced Nausea and Vomiting Treatment Historic Market Size by Application (2018-2024)
5.2 Global Chemotherapy-induced Nausea and Vomiting Treatment Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Chemotherapy-induced Nausea and Vomiting Treatment Market Size (2018-2034)
6.2 North America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Type
6.2.1 North America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Type (2018-2024)
6.2.2 North America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Type (2024-2034)
6.2.3 North America Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Type (2018-2034)
6.3 North America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Application
6.3.1 North America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Application (2018-2024)
6.3.2 North America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Application (2024-2034)
6.3.3 North America Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Application (2018-2034)
6.4 North America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Country
6.4.1 North America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Country: 2018 VS 2022 VS 2034
6.4.2 North America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Country (2018-2024)
6.4.3 North America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Country (2024-2034)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Chemotherapy-induced Nausea and Vomiting Treatment Market Size (2018-2034)
7.2 Europe Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Type
7.2.1 Europe Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Type (2018-2024)
7.2.2 Europe Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Type (2024-2034)
7.2.3 Europe Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Type (2018-2034)
7.3 Europe Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Application
7.3.1 Europe Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Application (2018-2024)
7.3.2 Europe Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Application (2024-2034)
7.3.3 Europe Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Application (2018-2034)
7.4 Europe Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Country
7.4.1 Europe Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Country (2018-2024)
7.4.3 Europe Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Country (2024-2034)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Chemotherapy-induced Nausea and Vomiting Treatment Market Size (2018-2034)
8.2 China Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Type
8.2.1 China Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Type (2018-2024)
8.2.2 China Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Type (2024-2034)
8.2.3 China Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Type (2018-2034)
8.3 China Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Application
8.3.1 China Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Application (2018-2024)
8.3.2 China Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Application (2024-2034)
8.3.3 China Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Application (2018-2034)
9 Asia (excluding China)
9.1 Asia Chemotherapy-induced Nausea and Vomiting Treatment Market Size (2018-2034)
9.2 Asia Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Type
9.2.1 Asia Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Type (2018-2024)
9.2.2 Asia Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Type (2024-2034)
9.2.3 Asia Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Type (2018-2034)
9.3 Asia Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Application
9.3.1 Asia Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Application (2018-2024)
9.3.2 Asia Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Application (2024-2034)
9.3.3 Asia Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Application (2018-2034)
9.4 Asia Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Region
9.4.1 Asia Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Region: 2018 VS 2022 VS 2034
9.4.2 Asia Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Region (2018-2024)
9.4.3 Asia Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Region (2024-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Chemotherapy-induced Nausea and Vomiting Treatment Market Size (2018-2034)
10.2 Middle East, Africa, and Latin America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Type
10.2.1 Middle East, Africa, and Latin America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Type (2018-2024)
10.2.2 Middle East, Africa, and Latin America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Type (2024-2034)
10.2.3 Middle East, Africa, and Latin America Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Type (2018-2034)
10.3 Middle East, Africa, and Latin America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Application
10.3.1 Middle East, Africa, and Latin America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Application (2018-2024)
10.3.2 Middle East, Africa, and Latin America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Application (2024-2034)
10.3.3 Middle East, Africa, and Latin America Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Application (2018-2034)
10.4 Middle East, Africa, and Latin America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Country
10.4.1 Middle East, Africa, and Latin America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa, and Latin America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Country (2018-2024)
10.4.3 Middle East, Africa, and Latin America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Country (2024-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Heron Therapeutics
11.1.1 Heron Therapeutics Company Details
11.1.2 Heron Therapeutics Business Overview
11.1.3 Heron Therapeutics Chemotherapy-induced Nausea and Vomiting Treatment Introduction
11.1.4 Heron Therapeutics Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
11.1.5 Heron Therapeutics Recent Developments
11.2 Merck
11.2.1 Merck Company Details
11.2.2 Merck Business Overview
11.2.3 Merck Chemotherapy-induced Nausea and Vomiting Treatment Introduction
11.2.4 Merck Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
11.2.5 Merck Recent Developments
11.3 Eisai
11.3.1 Eisai Company Details
11.3.2 Eisai Business Overview
11.3.3 Eisai Chemotherapy-induced Nausea and Vomiting Treatment Introduction
11.3.4 Eisai Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
11.3.5 Eisai Recent Developments
11.4 Mundipharma
11.4.1 Mundipharma Company Details
11.4.2 Mundipharma Business Overview
11.4.3 Mundipharma Chemotherapy-induced Nausea and Vomiting Treatment Introduction
11.4.4 Mundipharma Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
11.4.5 Mundipharma Recent Developments
11.5 Qilu Pharma
11.5.1 Qilu Pharma Company Details
11.5.2 Qilu Pharma Business Overview
11.5.3 Qilu Pharma Chemotherapy-induced Nausea and Vomiting Treatment Introduction
11.5.4 Qilu Pharma Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
11.5.5 Qilu Pharma Recent Developments
11.6 Teva
11.6.1 Teva Company Details
11.6.2 Teva Business Overview
11.6.3 Teva Chemotherapy-induced Nausea and Vomiting Treatment Introduction
11.6.4 Teva Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
11.6.5 Teva Recent Developments
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Chemotherapy-induced Nausea and Vomiting Treatment Introduction
11.7.4 Novartis Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
11.7.5 Novartis Recent Developments
11.8 Roche
11.8.1 Roche Company Details
11.8.2 Roche Business Overview
11.8.3 Roche Chemotherapy-induced Nausea and Vomiting Treatment Introduction
11.8.4 Roche Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
11.8.5 Roche Recent Developments
11.9 Mylan
11.9.1 Mylan Company Details
11.9.2 Mylan Business Overview
11.9.3 Mylan Chemotherapy-induced Nausea and Vomiting Treatment Introduction
11.9.4 Mylan Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
11.9.5 Mylan Recent Developments
11.10 Baxter
11.10.1 Baxter Company Details
11.10.2 Baxter Business Overview
11.10.3 Baxter Chemotherapy-induced Nausea and Vomiting Treatment Introduction
11.10.4 Baxter Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
11.10.5 Baxter Recent Developments
11.11 GSK
11.11.1 GSK Company Details
11.11.2 GSK Business Overview
11.11.3 GSK Chemotherapy-induced Nausea and Vomiting Treatment Introduction
11.11.4 GSK Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
11.11.5 GSK Recent Developments
11.12 Helsinn
11.12.1 Helsinn Company Details
11.12.2 Helsinn Business Overview
11.12.3 Helsinn Chemotherapy-induced Nausea and Vomiting Treatment Introduction
11.12.4 Helsinn Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
11.12.5 Helsinn Recent Developments
11.13 Southwest Pharma
11.13.1 Southwest Pharma Company Details
11.13.2 Southwest Pharma Business Overview
11.13.3 Southwest Pharma Chemotherapy-induced Nausea and Vomiting Treatment Introduction
11.13.4 Southwest Pharma Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
11.13.5 Southwest Pharma Recent Developments
11.14 Haisco
11.14.1 Haisco Company Details
11.14.2 Haisco Business Overview
11.14.3 Haisco Chemotherapy-induced Nausea and Vomiting Treatment Introduction
11.14.4 Haisco Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
11.14.5 Haisco Recent Developments
11.15 Sun Pharma
11.15.1 Sun Pharma Company Details
11.15.2 Sun Pharma Business Overview
11.15.3 Sun Pharma Chemotherapy-induced Nausea and Vomiting Treatment Introduction
11.15.4 Sun Pharma Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
11.15.5 Sun Pharma Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Chemotherapy-induced Nausea and Vomiting Treatment Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2034
Table 2. Key Players of 5-HT3 Inhibitors
Table 3. Key Players of NK1 Inhibitors
Table 4. Key Players of Other
Table 5. Global Chemotherapy-induced Nausea and Vomiting Treatment Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2034
Table 6. Global Chemotherapy-induced Nausea and Vomiting Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 7. Global Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Region (2018-2024) & (US$ Million)
Table 8. Global Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Region (2018-2024)
Table 9. Global Chemotherapy-induced Nausea and Vomiting Treatment Forecasted Market Size by Region (2024-2034) & (US$ Million)
Table 10. Global Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Region (2024-2034)
Table 11. Chemotherapy-induced Nausea and Vomiting Treatment Market Trends
Table 12. Chemotherapy-induced Nausea and Vomiting Treatment Market Drivers
Table 13. Chemotherapy-induced Nausea and Vomiting Treatment Market Challenges
Table 14. Chemotherapy-induced Nausea and Vomiting Treatment Market Restraints
Table 15. Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue by Players (2018-2024) & (US$ Million)
Table 16. Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue Share by Players (2018-2024)
Table 17. Global Top Chemotherapy-induced Nausea and Vomiting Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chemotherapy-induced Nausea and Vomiting Treatment as of 2022)
Table 18. Global Chemotherapy-induced Nausea and Vomiting Treatment Industry Ranking 2021 VS 2022 VS 2024
Table 19. Global 5 Largest Players Market Share by Chemotherapy-induced Nausea and Vomiting Treatment Revenue (CR5 and HHI) & (2018-2024)
Table 20. Global Key Players of Chemotherapy-induced Nausea and Vomiting Treatment, Headquarters and Area Served
Table 21. Global Key Players of Chemotherapy-induced Nausea and Vomiting Treatment, Product and Application
Table 22. Global Key Players of Chemotherapy-induced Nausea and Vomiting Treatment, Product and Application
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 25. Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue Market Share by Type (2018-2024)
Table 26. Global Chemotherapy-induced Nausea and Vomiting Treatment Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 27. Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue Market Share by Type (2024-2034)
Table 28. Global Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 29. Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue Share by Application (2018-2024)
Table 30. Global Chemotherapy-induced Nausea and Vomiting Treatment Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 31. Global Chemotherapy-induced Nausea and Vomiting Treatment Revenue Share by Application (2024-2034)
Table 32. North America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 33. North America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Type (2024-2034) & (US$ Million)
Table 34. North America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 35. North America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Application (2024-2034) & (US$ Million)
Table 36. North America Chemotherapy-induced Nausea and Vomiting Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 37. North America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Country (2018-2024) & (US$ Million)
Table 38. North America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Country (2024-2034) & (US$ Million)
Table 39. Europe Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 40. Europe Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Type (2024-2034) & (US$ Million)
Table 41. Europe Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 42. Europe Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Application (2024-2034) & (US$ Million)
Table 43. Europe Chemotherapy-induced Nausea and Vomiting Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 44. Europe Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Country (2018-2024) & (US$ Million)
Table 45. Europe Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Country (2024-2034) & (US$ Million)
Table 46. China Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 47. China Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Type (2024-2034) & (US$ Million)
Table 48. China Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 49. China Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Application (2024-2034) & (US$ Million)
Table 50. Asia Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 51. Asia Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Type (2024-2034) & (US$ Million)
Table 52. Asia Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 53. Asia Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Application (2024-2034) & (US$ Million)
Table 54. Asia Chemotherapy-induced Nausea and Vomiting Treatment Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 55. Asia Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Region (2018-2024) & (US$ Million)
Table 56. Asia Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Region (2024-2034) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Type (2024-2034) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Application (2024-2034) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Chemotherapy-induced Nausea and Vomiting Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 62. Middle East, Africa, and Latin America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Country (2018-2024) & (US$ Million)
Table 63. Middle East, Africa, and Latin America Chemotherapy-induced Nausea and Vomiting Treatment Market Size by Country (2024-2034) & (US$ Million)
Table 64. Heron Therapeutics Company Details
Table 65. Heron Therapeutics Business Overview
Table 66. Heron Therapeutics Chemotherapy-induced Nausea and Vomiting Treatment Product
Table 67. Heron Therapeutics Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024) & (US$ Million)
Table 68. Heron Therapeutics Recent Developments
Table 69. Merck Company Details
Table 70. Merck Business Overview
Table 71. Merck Chemotherapy-induced Nausea and Vomiting Treatment Product
Table 72. Merck Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024) & (US$ Million)
Table 73. Merck Recent Developments
Table 74. Eisai Company Details
Table 75. Eisai Business Overview
Table 76. Eisai Chemotherapy-induced Nausea and Vomiting Treatment Product
Table 77. Eisai Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024) & (US$ Million)
Table 78. Eisai Recent Developments
Table 79. Mundipharma Company Details
Table 80. Mundipharma Business Overview
Table 81. Mundipharma Chemotherapy-induced Nausea and Vomiting Treatment Product
Table 82. Mundipharma Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024) & (US$ Million)
Table 83. Mundipharma Recent Developments
Table 84. Qilu Pharma Company Details
Table 85. Qilu Pharma Business Overview
Table 86. Qilu Pharma Chemotherapy-induced Nausea and Vomiting Treatment Product
Table 87. Qilu Pharma Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024) & (US$ Million)
Table 88. Qilu Pharma Recent Developments
Table 89. Teva Company Details
Table 90. Teva Business Overview
Table 91. Teva Chemotherapy-induced Nausea and Vomiting Treatment Product
Table 92. Teva Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024) & (US$ Million)
Table 93. Teva Recent Developments
Table 94. Novartis Company Details
Table 95. Novartis Business Overview
Table 96. Novartis Chemotherapy-induced Nausea and Vomiting Treatment Product
Table 97. Novartis Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024) & (US$ Million)
Table 98. Novartis Recent Developments
Table 99. Roche Company Details
Table 100. Roche Business Overview
Table 101. Roche Chemotherapy-induced Nausea and Vomiting Treatment Product
Table 102. Roche Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024) & (US$ Million)
Table 103. Roche Recent Developments
Table 104. Mylan Company Details
Table 105. Mylan Business Overview
Table 106. Mylan Chemotherapy-induced Nausea and Vomiting Treatment Product
Table 107. Mylan Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024) & (US$ Million)
Table 108. Mylan Recent Developments
Table 109. Baxter Company Details
Table 110. Baxter Business Overview
Table 111. Baxter Chemotherapy-induced Nausea and Vomiting Treatment Product
Table 112. Baxter Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024) & (US$ Million)
Table 113. Baxter Recent Developments
Table 114. GSK Company Details
Table 115. GSK Business Overview
Table 116. GSK Chemotherapy-induced Nausea and Vomiting Treatment Product
Table 117. GSK Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024) & (US$ Million)
Table 118. GSK Recent Developments
Table 119. Helsinn Company Details
Table 120. Helsinn Business Overview
Table 121. Helsinn Chemotherapy-induced Nausea and Vomiting Treatment Product
Table 122. Helsinn Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024) & (US$ Million)
Table 123. Helsinn Recent Developments
Table 124. Southwest Pharma Company Details
Table 125. Southwest Pharma Business Overview
Table 126. Southwest Pharma Chemotherapy-induced Nausea and Vomiting Treatment Product
Table 127. Southwest Pharma Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024) & (US$ Million)
Table 128. Southwest Pharma Recent Developments
Table 129. Haisco Company Details
Table 130. Haisco Business Overview
Table 131. Haisco Chemotherapy-induced Nausea and Vomiting Treatment Product
Table 132. Haisco Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024) & (US$ Million)
Table 133. Haisco Recent Developments
Table 134. Sun Pharma Company Details
Table 135. Sun Pharma Business Overview
Table 136. Sun Pharma Chemotherapy-induced Nausea and Vomiting Treatment Product
Table 137. Sun Pharma Revenue in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024) & (US$ Million)
Table 138. Sun Pharma Recent Developments
Table 139. Research Programs/Design for This Report
Table 140. Key Data Information from Secondary Sources
Table 141. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Chemotherapy-induced Nausea and Vomiting Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 2. Global Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Type: 2022 VS 2034
Figure 3. 5-HT3 Inhibitors Features
Figure 4. NK1 Inhibitors Features
Figure 5. Other Features
Figure 6. Global Chemotherapy-induced Nausea and Vomiting Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 7. Global Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Application: 2022 VS 2034
Figure 8. Acute CINV Case Studies
Figure 9. Delayed CINV Case Studies
Figure 10. Breakthrough CINV Case Studies
Figure 11. Others Case Studies
Figure 12. Chemotherapy-induced Nausea and Vomiting Treatment Report Years Considered
Figure 13. Global Chemotherapy-induced Nausea and Vomiting Treatment Market Size (US$ Million), Year-over-Year: 2018-2034
Figure 14. Global Chemotherapy-induced Nausea and Vomiting Treatment Market Size, (US$ Million), 2018 VS 2022 VS 2034
Figure 15. Global Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Region: 2022 VS 2034
Figure 16. Global Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Players in 2022
Figure 17. Global Top Chemotherapy-induced Nausea and Vomiting Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chemotherapy-induced Nausea and Vomiting Treatment as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Chemotherapy-induced Nausea and Vomiting Treatment Revenue in 2022
Figure 19. North America Chemotherapy-induced Nausea and Vomiting Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 20. North America Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Type (2018-2034)
Figure 21. North America Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Application (2018-2034)
Figure 22. North America Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Country (2018-2034)
Figure 23. United States Chemotherapy-induced Nausea and Vomiting Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 24. Canada Chemotherapy-induced Nausea and Vomiting Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 25. Europe Chemotherapy-induced Nausea and Vomiting Treatment Market Size YoY (2018-2034) & (US$ Million)
Figure 26. Europe Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Type (2018-2034)
Figure 27. Europe Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Application (2018-2034)
Figure 28. Europe Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Country (2018-2034)
Figure 29. Germany Chemotherapy-induced Nausea and Vomiting Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 30. France Chemotherapy-induced Nausea and Vomiting Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 31. U.K. Chemotherapy-induced Nausea and Vomiting Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 32. Italy Chemotherapy-induced Nausea and Vomiting Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 33. Russia Chemotherapy-induced Nausea and Vomiting Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 34. Nordic Countries Chemotherapy-induced Nausea and Vomiting Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 35. China Chemotherapy-induced Nausea and Vomiting Treatment Market Size YoY (2018-2034) & (US$ Million)
Figure 36. China Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Type (2018-2034)
Figure 37. China Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Application (2018-2034)
Figure 38. Asia Chemotherapy-induced Nausea and Vomiting Treatment Market Size YoY (2018-2034) & (US$ Million)
Figure 39. Asia Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Type (2018-2034)
Figure 40. Asia Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Application (2018-2034)
Figure 41. Asia Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Region (2018-2034)
Figure 42. Japan Chemotherapy-induced Nausea and Vomiting Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 43. South Korea Chemotherapy-induced Nausea and Vomiting Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 44. China Taiwan Chemotherapy-induced Nausea and Vomiting Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 45. Southeast Asia Chemotherapy-induced Nausea and Vomiting Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 46. India Chemotherapy-induced Nausea and Vomiting Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 47. Australia Chemotherapy-induced Nausea and Vomiting Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Chemotherapy-induced Nausea and Vomiting Treatment Market Size YoY (2018-2034) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Type (2018-2034)
Figure 50. Middle East, Africa, and Latin America Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Application (2018-2034)
Figure 51. Middle East, Africa, and Latin America Chemotherapy-induced Nausea and Vomiting Treatment Market Share by Country (2018-2034)
Figure 52. Brazil Chemotherapy-induced Nausea and Vomiting Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 53. Mexico Chemotherapy-induced Nausea and Vomiting Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 54. Turkey Chemotherapy-induced Nausea and Vomiting Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 55. Saudi Arabia Chemotherapy-induced Nausea and Vomiting Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 56. Israel Chemotherapy-induced Nausea and Vomiting Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 57. GCC Countries Chemotherapy-induced Nausea and Vomiting Treatment Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 58. Heron Therapeutics Revenue Growth Rate in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
Figure 59. Merck Revenue Growth Rate in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
Figure 60. Eisai Revenue Growth Rate in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
Figure 61. Mundipharma Revenue Growth Rate in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
Figure 62. Qilu Pharma Revenue Growth Rate in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
Figure 63. Teva Revenue Growth Rate in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
Figure 64. Novartis Revenue Growth Rate in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
Figure 65. Roche Revenue Growth Rate in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
Figure 66. Mylan Revenue Growth Rate in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
Figure 67. Baxter Revenue Growth Rate in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
Figure 68. GSK Revenue Growth Rate in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
Figure 69. Helsinn Revenue Growth Rate in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
Figure 70. Southwest Pharma Revenue Growth Rate in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
Figure 71. Haisco Revenue Growth Rate in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
Figure 72. Sun Pharma Revenue Growth Rate in Chemotherapy-induced Nausea and Vomiting Treatment Business (2018-2024)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries